Condition: Cancer · Sponsor: Jounce Therapeutics, Inc.
JTX-2011-201 is a Phase 2, open label clinical study of vopratelimab (JTX-2011) and ipilimumab in adult subjects with non-small cell lung cancer (NSCLC) or urothelial cancer to evaluate safety and efficacy.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Beverly Hills Cancer Center | Beverly Hills, California, United States | — |
| University of Southern California Medical Center | Los Angeles, California, United States | — |
| Christiana Care Health Services | Newark, Delaware, United States | — |
| Florida Cancer Specialists Sarasota Cattlemen | Sarasota, Florida, United States | — |
| University of Maryland - Marlene and Stewart Greenebaum Cancer Center | Baltimore, Maryland, United States | — |
| Massachusetts General Hospital | Boston, Massachusetts, United States | — |
| Washington University School of Medicine | St Louis, Missouri, United States | — |
| The Valley Hospital | Ridgewood, New Jersey, United States | — |
| Weill Cornell Medical College | New York, New York, United States | — |
| University of Rochester | Rochester, New York, United States | — |
| Southeastern Medical Oncology Center | Clinton, North Carolina, United States | — |
| Cleveland Clinic Foundation | Cleveland, Ohio, United States | — |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03989362